ARWR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arrowhead Pharmaceuticals Inc (ARWR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows strong technical indicators, positive analyst sentiment, and a favorable options sentiment, making it a solid choice for long-term growth potential.
The MACD histogram is positive and expanding (0.609), indicating bullish momentum. RSI is at 75.132, in the neutral zone but leaning towards overbought. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above key pivot levels (Pivot: 76.57, R1: 82.314, R2: 85.863), suggesting upward momentum.
Analysts have raised price targets significantly, with targets ranging from $46 to $100, reflecting strong confidence in the company's growth potential.
Positive momentum ahead of Phase 3 data for severe hypertriglyceridemia in Q3
Strong launch of Redemplo with a growing total addressable market.
Favorable FDA leadership changes benefiting biotech companies.
No significant hedge fund or insider trading activity, indicating a lack of strong institutional conviction.
Comparisons with competitor INHBE data have raised some questions, though this appears largely priced in.
No financial data available for the latest quarter, but analysts highlight strong sales potential for Redemplo and a diversified RNAi portfolio.
Analysts are overwhelmingly positive, with multiple upgrades and raised price targets. Recent ratings include Overweight from JPMorgan ($88 target), Overweight from Morgan Stanley ($100 target), and Buy from BofA ($93 target). The consensus reflects strong confidence in the company's growth prospects.
